Countable Labs Brings Ultra-Precise PCR to Europe, Challenging Industry Giants

PALO ALTO, CA – March 25, 2026 – A new era of molecular measurement is dawning in Europe as California-based Countable Labs officially launches its highly anticipated Countable 4 Platform, following the achievement of CE Mark clearance. The move introduces the company’s groundbreaking Countable PCR technology—a single-molecule, counting-based system—to a market hungry for greater precision in diagnostics, biomanufacturing, and life sciences research.

Backed by over $70 million in funding from top-tier life sciences investors, Countable Labs is poised to challenge the established order in the competitive molecular diagnostics space. The company claims its technology offers a tenfold increase in sensitivity and precision over existing PCR solutions, a leap forward that could have profound implications for everything from cancer detection to the manufacturing of advanced cell and gene therapies.

A New Standard in Molecular Precision

At the heart of the Countable 4 Platform is a fundamental shift away from the estimation-based methods of traditional PCR. For decades, quantitative PCR (qPCR) has relied on standard curves, while more recent digital PCR (dPCR) uses statistical inference—known as Poisson statistics—to estimate the number of target molecules in a sample. Countable PCR, however, promises to eliminate the ambiguity.

As the name implies, the technology is designed to directly count individual DNA or RNA molecules, providing what the company calls “true single-molecule quantification.” This direct-counting approach circumvents the statistical guesswork, enabling a level of accuracy previously unattainable. According to Countable Labs, the platform can reliably identify rare genetic variants that make up as little as 0.004% of a sample’s total genetic material. This is a significant improvement over many current dPCR systems, which typically operate in the 0.1% to 0.01% detection range.

For scientists and clinicians, this enhanced sensitivity is critical. It represents the ability to find the proverbial “needle in a haystack”—detecting a few cancerous cells in a blood sample for early diagnosis, identifying trace amounts of a viral pathogen, or verifying the purity of a life-saving gene therapy product with unparalleled confidence.

“Countable PCR represents a genuine leap forward in molecular quantification,” said David Dobnik, Ph.D., Assistant Professor at the National Institute of Biology, in a statement. “I like the simplicity of direct target counting, rather than relying on Poisson-based inference. Countable PCR handles quantification of challenging samples, such as rare targets against a high background matrix, with remarkable precision.”

Targeting Europe's High-Stakes Biotech Arena

The entry into Europe is more than just a geographical expansion; it's a strategic move into one of the world's most advanced and stringently regulated markets. By securing the CE Mark, Countable Labs has demonstrated that its platform meets the rigorous requirements of the European Union's In Vitro Diagnostic Regulation (IVDR), a comprehensive legal framework that governs device safety and performance.

This regulatory milestone allows the company to compete directly with established industry giants like Bio-Rad, Thermo Fisher Scientific, and Qiagen. Countable Labs is banking on its technological superiority to carve out a significant market share, particularly in high-value sectors.

“Achieving CE mark is a pivotal moment for Countable Labs as it expands our reach to support European customers,” stated Giovanna Prout, the company’s CEO. She emphasized that the technology bridges the gap between older PCR generations and next-generation sequencing, offering “clear data, immediate results, less instrument variability, and economics that make decentralization possible.”

The platform's design appears purpose-built for the exacting demands of biopharmaceutical manufacturing. Its inclusion of CFR part 11 compliant software is a key feature, ensuring that all data is secure, traceable, and ready for regulatory audits—a non-negotiable requirement in GMP (Good Manufacturing Practice) environments.

Accelerating the Future of Advanced Therapies

Perhaps nowhere is the need for precision more acute than in the booming field of cell and gene therapy. Manufacturing these complex biological treatments involves immense quality control challenges, such as accurately quantifying the genomic titer and integrity of viral vectors like AAV and measuring harmful impurities.

Inaccuracies in these measurements can compromise patient safety and lead to failed manufacturing batches, costing millions and delaying critical treatments. Countable Labs is positioning its platform as the definitive solution to these challenges. By providing audit-ready data with exceptional precision, the Countable 4 Platform aims to de-risk and streamline the manufacturing process for cell and gene therapy pioneers.

This focus on a critical bottleneck in an explosive industry is a calculated move. As more advanced therapies move from research to clinical reality, the demand for reliable and ultra-precise quantification tools is set to skyrocket. Countable Labs is arriving in Europe ready to meet that demand.

“European biopharma and industrial customers face the same precision demands as their U.S. counterparts, and they deserve access to best-in-class quantification solutions,” said Dries Van Hemelen, Ph.D., who heads the company’s sales and support for the region. “We're ready to support them as they experience a better way to approach PCR testing to advance innovation.”

Scientific Scrutiny and Investor Confidence

Founded in 2019 by genomics veterans Stephen Fodor, Ari Chaney, and Christina Fan, Countable Labs (formerly Enumerix) has the backing of a formidable syndicate of investors, including ARCH Venture Partners and F-Prime Capital. This strong financial footing provides the resources needed to challenge incumbents and drive market adoption.

While the company's claims are bold, they are beginning to be validated by the scientific community. The endorsement from Dr. Dobnik provides early third-party credibility, and his upcoming presentation at the prestigious American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2026 is expected to provide a detailed look at the technology's performance in characterizing DNA impurities in rAAV products.

With its technology now available in Europe, Countable Labs is set to transition from a promising developer to a major commercial player. The convergence of cutting-edge technology, strategic market focus, and robust regulatory approval signals that the European landscape for molecular measurement may be on the verge of a significant transformation.